Lundbeck opens pharma plant in China

Published: 10-Dec-2012

Will initially focus on treatments for Alzheimer’s disease


Danish pharmaceutical firm Lundbeck has finished construction of its first factory in China, in the XEDA International Industrial Park, Tianjin.

The plant will initially focus on producing Alzheimer’s disease treatments, repackaging Lundbeck’s Ebixa medicine for the Chinese market.

The company said the investment ‘demonstrates Lundbeck’s long term commitment to China’ and will ‘ensure better control of the supply chain in the Chinese market’.

Herman Santoni, president and general manager of Lundbeck China, said his company wants to launch three new medicines in China, focusing on mood disorders, alcoholism and Parkinson’s disease.

With licences and good manufacturing certification now being secured, the aim is to start selling medicines by April 2013, or earlier.

The project follows the company’s launch of a research and development centre in Shanghai in 2011. Lundbeck (Beijing) Pharmaceutical Consulting Co is headquartered in Beijing.

  • Companies:
  • Lundbeck
See more

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Read more
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment

Upcoming event

Interphex

16-18 April 2024 | Conference and Exhibition | New York, US See all

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving to continuous processes

As both the regulators and equipment manufacturers push the concept of continuous manufacturing, the mindset is filtering down from research and API production to finished products. But are all the requirements in place to make it successful? Susan Birks reports
Finance

Lundbeck embarks on another restructuring to drive profit and ensure growth

Will cut around 1,000 jobs in Europe
Media

Alzheimer’s treatment market value to exceed US$13bn by 2023

Rising prevalence, advances in diagnostic capability and greater awareness will drive growth
Finance

Lundbeck to buy Chelsea Therapeutics for US$658m

Danish company gains rights to FDA-approved Northera for the treatment of neurological disorders
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Finance

New products drive growth at Lundbeck in 2013

Received five approvals from US and European regulators
Subscribe now